Spero Therapeutics Inc
Research Spero Therapeutics Inc (SPRO) on Bullrun: valuation model: 17.2% undervalued, market cap USD 69.78M, P/E 11.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPRO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal17.2% undervalued
- Market capUSD 69.78M
- P/E11.0
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 9.55M
- Free cash flow-USD 5.36M
Valuation Snapshot
Bullrun's latest valuation model marks Spero Therapeutics Inc as 17.2% undervalued; latest market cap is USD 69.78M; P/E is 11.0.
Peer valuation comparison
Latest P/E is 11x versus a Healthcare sector median of 24.64x (55.4% below).
Latest P/E is 11x versus a United States median of 23.85x (53.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 12.59M | USD 8.57M | -USD 12.62M | n/a | 0.15 | USD 40.27M | USD 2.90M | USD 59.02M |
| FY2024 | USD 371.00K | -USD 68.57M | -USD 23.44M | n/a | -1.27 | USD 52.89M | USD 4.30M | USD 46.12M |
| FY2023 | USD 933.00K | USD 22.81M | -USD 33.00M | n/a | 0.43 | USD 76.33M | USD 5.54M | USD 106.89M |
| FY2022 | USD 2.50M | -USD 46.42M | -USD 7.73M | n/a | -1.23 | USD 109.11M | USD 6.65M | USD 75.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 69.78M | 11.0 | n/a | n/a |
| 2025 | 2025-12-31 | USD 131.45M | 19.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 56.23M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 77.91M | 147.0 | n/a | n/a |
| 2022 | 2022-12-30 | USD 89.57M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 518.62M | n/a | n/a | n/a |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Spero Therapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Spero Therapeutics Inc as 17.2% undervalued.
What is Spero Therapeutics Inc's market cap?
Spero Therapeutics Inc's market capitalization is USD 69.78M.
What is Spero Therapeutics Inc's P/E ratio?
Spero Therapeutics Inc's price-to-earnings (P/E) ratio is 11.0.
What does Spero Therapeutics Inc do?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd.